Analysts have clear opinions on DERM.
There are 4 analysts on the Wall offering 12 month price targets for Dermira in the last 3 months. The average price target is $18.80 with a high forecast of $18.80 and a low forecast of $18.80. The average price target represents a 0.32% increase from the last price of $18.74.
Dermira, Inc. (DERM) is followed by 4 analysts on the street.
Seamus Fernandez from Guggenheim rates it a Hold.
Similarly, 20 days ago Serge Belanger of Needham Downgraded a Hold with a target of —.
The consensus on the street is null.
What does Dermira, Inc.(DERM) do ?
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.
Dermira, Inc. (DERM) Insider Trades
Looking for stocks just like DERM?
Based on Wall Street analyst research, several stocks are similar to DERM
– NOVN [Info can be found here: https://www.nasdaq.com/market-activity/stocks/NOVN ]
– RVNC [Info can be found here: https://www.nasdaq.com/market-activity/stocks/RVNC ]
– ACRS [Info can be found here: https://www.nasdaq.com/market-activity/stocks/ACRS ]